LTβR Activators
The chemical class of 'Indirect LTβR Activators' comprises a range of compounds known to modulate various signaling pathways, which in turn can influence LTβR activity. These compounds target specific signaling molecules and enzymes, indirectly impacting the signaling cascade associated with LTβR. For example, Bay 11-7082, an NF-κB pathway inhibitor, may indirectly enhance LTβR signaling by modulating the NF-κB pathway, which is a downstream effector of LTβR. Similarly, inhibitors like SP600125 (JNK), sc-514 (IKKβ), and SB203580 (p38 MAPK) target key components of the MAPK and NF-κB pathways, potentially leading to altered LTβR signaling.
Compounds such as LY294002 and MK-2206, which inhibit PI3K and AKT respectively, demonstrate the interconnectivity of cellular signaling networks. By modulating the PI3K/AKT pathway, they could create a cellular environment that indirectly influences LTβR activity. Similarly, Rapamycin (an mTOR inhibitor) and AICAR (an AMPK activator) impact metabolic and growth-related pathways, which can intersect with LTβR signaling. This class also includes compounds like Lithium Chloride and Resveratrol, which target GSK-3β and sirtuins, respectively.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
Inhibits NF-κB activation by blocking the phosphorylation of IκBα. This inhibition may lead to compensatory feedback mechanisms that enhance LTβR signaling to maintain NF-κB activity. | ||||||
SC514 | 354812-17-2 | sc-205504 sc-205504A | 5 mg 10 mg | $67.00 $91.00 | 13 | |
Inhibits IKKβ, a kinase in the NF-κB pathway. This inhibition may increase LTβR signaling as a compensatory mechanism to activate NF-κB through alternative routes. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
Inhibits p38 MAPK, potentially leading to increased signaling through other MAPK pathways, including those activated by LTβR, in a compensatory response. | ||||||
(5Z)-7-Oxozeaenol | 253863-19-3 | sc-202055 sc-202055A | 1 mg 5 mg | $157.00 $646.00 | 13 | |
Inhibits TAK1, a kinase that mediates both NF-κB and MAPK pathways. Inhibition could enhance LTβR signaling as the cell seeks alternative pathways to activate NF-κB and MAPK. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
Inhibits PI3K, which may lead to enhanced LTβR signaling as part of a cellular response to maintain balanced signaling through other pathways like NF-κB or MAPK. | ||||||
MK-2206 dihydrochloride | 1032350-13-2 | sc-364537 sc-364537A | 5 mg 10 mg | $182.00 $332.00 | 67 | |
Inhibits AKT, leading to potential compensatory upregulation in LTβR signaling as part of the cellular response to maintain survival and proliferation signals. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Inhibits mTOR, which might enhance LTβR signaling due to compensatory responses in growth and survival pathways, of which LTβR is a part. | ||||||
AICAR | 2627-69-2 | sc-200659 sc-200659A sc-200659B | 50 mg 250 mg 1 g | $65.00 $280.00 $400.00 | 48 | |
Activates AMPK, leading to altered cellular energy balance, which could indirectly stimulate LTβR signaling in response to metabolic stress. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Inhibits GSK-3β, potentially leading to increased NF-κB activity, which might indirectly enhance LTβR signaling as part of the NF-κB regulatory network. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $80.00 $220.00 $460.00 | 64 | |
Activates sirtuins, which could lead to changes in cellular stress responses and indirectly enhance LTβR signaling as part of a broader adaptation to stress. | ||||||